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WHY STATISTICAL SIGNIFICANCE
ALONE IS NOT A SUFFICIENT BASIS
TO INTERPRET THE FINDINGS OF A
STATISTICAL ANALYSIS
Medical statistics plays a key role in clin-
ical research by helping to avoid errors of
interpretation due to the play of chance.
It is, however, critical to understand the
limits of what statistical analysis provides
and interpret the ﬁndings accordingly.
Statistical analysis can summarise the stat-
istical evidence but it cannot tell us
whether a difference is important per se,
as clinical judgement is needed. Suppose
we have a clinical trial which compares
two drugs for reducing the intraocular
pressure (IOP) in the eye and there is evi-
dence of a statistically signiﬁcant differ-
ence in favour of drug A. Does this mean
A is superior to B? Perhaps, if the average
difference is 5 mm Hg but what if it is
only 0.1 mmg Hg? We would be very
unlikely to conclude clinical superiority
under these circumstances, or at least it
would be necessary to take account of dif-
ferences in other key outcomes such as
adverse events before reaching such a con-
clusion. It might be thought that the
p value from a statistical hypothesis test
can serve this purpose but this is not the
case. Solely considering whether a p value
is ‘statistically signiﬁcant’ is not a sufﬁ-
cient basis to interpret the ﬁndings of a
statistical analysis. There is a number of
reasons why this is the case.
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▸ First, when a statistical hypothesis test
is performed we are usually implicitly
testing for evidence of a difference of
any magnitude. To equate this differ-
ence to clinical importance is to view
all statistically signiﬁcant differences as
clinically important and of equal value
(at least in a practical sense). Clearly, as
in the IOP example above, this may
not be the case.
▸ Second, the p value is not a direct
measure of the strength of evidence for
the null hypothesis. Instead, it is the
probability of obtaining a result as, or
more extreme than, the one observed
assuming the null hypothesis is true. It
is therefore, at best, a partial and indir-
ect measure of the evidence regarding
the truth of the null hypothesis. In par-
ticular, it is not the probability that the
null hypothesis is true given the data.
▸ Third, the criterion used for statistical
signiﬁcance, typically a p value of less
than 0.05 (ie, 5% signiﬁcance level), is
arbitrary. It is based on convention
rather than statistical theory. It guards
against making one type of error too
often (rejecting the null hypothesis
when it is true), but gives no protec-
tion against making the other type of
error (not rejecting the null hypothesis
when it is false).
▸ Fourth, even once we meet our criteria
we must take into consideration the
magnitude of an effect. It’s all ﬁne and
well saying we have found a signiﬁcant
difference, but it is crucial to consider
how big this difference is and whether
we view it as clinically important. We
should design our study such that the
difference which would be statistically
signiﬁcant would also be considered to
be clinically important. It is also true,
as covered in an earlier BJO statistics
note,
3 that when we don’t ﬁnd a statis-
tically signiﬁcant difference, we must
consider how precise our estimate is
(the width of our CI) and what magni-
tude of effect would be important to
us if it did truly exist. A p value
neither quantiﬁes the size of an
observed effect nor its importance.
EFFECT SIZE MATTERS
Wherever possible, a statistical method
should be used that can estimate the mag-
nitude of the observed effect (an effect
size) along with the associated uncertainty
around this estimate, rather than only
carrying out a statistical (hypothesis) test
and presenting the corresponding p value.
In the commonest situation of comparing
two independent groups, a t test and cor-
responding CI for the difference in means
is preferred, provided its underlying
assumptions hold, over a non-parametric
alternative such as a Mann–Whitney
U test (it should be noted that this non-
parametric test does not compare the
group means or medians but the two dis-
tributions). Effect measures differ accord-
ing to the type of outcome often with
several alternatives available. Common
effect measures for binary outcomes
include differences in proportions, risk
ratios or ORs. A HR (which may be
interpreted similarly to a relative risk)
can be used for time-to-event data. These
effect measures are often natural pro-
ducts of a particular statistical analysis
(eg, a Cox regression analysis for
time-to-event data estimates HRs, logistic
regression for a dichotomous outcome
estimates ORs). We note in passing that a
Bayesian statistical approach offers a the-
oretically appealing alternative to con-
ventional statistical testing which avoids
the use of p values although not without
difﬁculties both in principles and
practice.
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The importance of considering the
effect size is illustrated in table 1 where
the results of four hypothetical trial scen-
arios are presented. The presence of any
ocular adverse event (eg, eye irritation,
dryness, eyelash growth) was compared
between two IOP-lowering drugs in
patients with open-angle glaucoma or
ocular hypertension. Comparing drug A
with drug B in scenarios 1, 2 and 3 using
Fisher’s exact test gives fairly similar
p values (between 0.026 and 0.125).
However, two of these p values are
smaller than 0.05 and one is not. If we
use the conventional cut-off of p=0.05
for statistical signiﬁcance, we would con-
clude that there was a statistically signiﬁ-
cant difference between drugs A and B in
scenarios 1 and 3, but no difference in
scenario 2. If we look at the effect sizes,
we see that scenarios 1 and 2 have an
observed difference of over 20% with
similar CI widths although the ﬁrst does
not contain a difference of zero whereas
the second does. Clearly, the strength of
evidence is similar for these scenarios,
with the caveat of statistical signiﬁcance
not being shown in the second (if the 5%
signiﬁcance level is adopted) but to ignore
the size of the effect would be foolish. On
a practical level, it is dangerous to rely
solely on a p value and censoring p values
which are above a cut-off (eg, p=0.054
being replaced by ‘NS’) is uninformative
and potentially misleading. Indeed
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pretation which are mitigated through the
use of point estimates and CIs of effect
sizes.
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The trials in scenarios 3 and 4 are
much larger (10 times the size) and there-
fore have greater statistical precision and
are able to detect substantially smaller
effects. If we were only to consider the
p value in scenario 1, we would conclude
that the drugs are different, but this pro-
vides no information about the magnitude
of the difference—which in this instance
is considerable. If we compare scenarios 1
and 3, we see that the p values are similar
but the effect sizes are very different
(23% vs 6%). If we compare scenarios 3
and 4, we see that both have much tighter
CIs with a difference in the rate of
adverse events that would be viewed as
‘clinically important’ likely to be ruled out
in scenario 4.
Interpreting the result of a statistical
analysis relies upon more than statistical
understanding. It is helpful to differentiate
between ‘statistical signiﬁcance’ and ‘clin-
ical importance’. If there is statistical evi-
dence of an effect, we wish to know if it
matters. Conversely, where there is no
statistical evidence of an effect, we wish
to know if a clinically important effect has
been ruled out. Calculating an effect size
and a corresponding 95% CI provides the
information upon which such judgements
can be made. It can be remarkably difﬁ-
cult to know what is clinically important
in a particular context. How easily clinical
importance can be assessed varies by the
setting, perspective adopted and outcome
analysed. Quality of life measures are
particularly difﬁcult to interpret, whereas
mortality is more straightforward. Avariety
of approaches of varying complexity have
been proposed (including minimal clinic-
ally important difference approaches)
which seek to provide a transparent, repro-
ducible and robust way to achieve this.
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SUMMARY
The magnitude of an observed effect and
the uncertainty regarding it should always
be considered when interpreting statistical
evidence. Whenever possible, a statistical
analysis which produces an effect size esti-
mate with associated uncertainty (eg, dif-
ference in means and its CI) rather than
solely a p value should be used and
reported.
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Table 1 Ocular adverse event rates from hypothetical randomised controlled trial scenarios
comparing a 12-week course of two IOP-lowering drugs for open-angle glaucoma
Scenario
Drug A
n/N (%)
Drug B
n/N (%)
Difference in percentages
(95% CI) p Value
1 1/30 (3) 8/30 (27) −23 (−41 to −5) 0.026
2 4/30 (13) 10/30 (33) −20 (−40 to 2) 0.125
3 28/300 (9) 45/300 (15) −6( −11 to −0.4) 0.045
4 6/300 (2) 9/300 (3) −1( −4 to 2) 0.603
Calculations were carried out in Stata
6 using command csi and rdcii; the p value is from a two-sided Fisher’s exact test
and the CI for the percentage difference is from Newcombe’s Method 10
7.
IOP, intraocular pressure; n, number of adverse events; N, number of patients.
Open Access
Scan to access more
free content
Cook JA, et al. Br J Ophthalmol May 2015 Vol 99 No 5 581
Editorial
group.bmj.com  on May 11, 2015 - Published by  http://bjo.bmj.com/ Downloaded from matter
Ophthalmic statistics note 6: effect sizes
behalf of the Ophthalmic Statistics Group
Jonathan A Cook, Catey Bunce, Caroline J Doré, Nick Freemantle and on
doi: 10.1136/bjophthalmol-2014-306303
26, 2015
2015 99: 580-581 originally published online February Br J Ophthalmol 
  http://bjo.bmj.com/content/99/5/580
Updated information and services can be found at: 
These include:
References
  #BIBL http://bjo.bmj.com/content/99/5/580
This article cites 7 articles, 5 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/ non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (443) Public health
 (956) Epidemiology
 (184) Open access
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com  on May 11, 2015 - Published by  http://bjo.bmj.com/ Downloaded from 